Endpoints News
Immutrin secures $86M for antibody program
A British biotech based in Cambridge, England, raised $86 million to advance an antibody drug designed to deplete protein deposits in people with amyloidosis.
The company, called Immutrin, was co-founded by Gregory Winter. He won …